Back to results
US 2022/0090015 A1Published application
Engineered immune cells with multiplex and localized activity
AssigneeA2 Biotherapeutics, Inc.
InventorAlexander Kamb
Life of this patent
Estimating the term…
Abstract
The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors, and exhibit multiplex and localized activity.
Claims20
An engineered immune cell comprising:
- activating and blocking receptors on a surface of the cell, wherein when the engineered immune cell encounters a tumor cell and a healthy cell:
- a first region of the activating and blocking receptors forms proximal to the healthy cell and blocking receptors in the first region inhibit cytotoxic effects on the healthy cell,
- while, simultaneously, a second region of the activating and blocking receptors forms proximal to the tumor cell and promotes a cytotoxic response by the engineered immune cell that exhibits cytotoxic effects on the tumor cell.
A method for treating cancer, the method comprising:
- providing an engineered immune cell to a patient, the engineered immune cell comprising activating and blocking cell-surface receptors, wherein when the engineered immune cell encounters a tumor cell and a healthy cell of the patient:
- a first set of the activating and blocking receptors collect into a first cell-surface region of the engineered immune cell proximal to the healthy cell in which the blocking receptors inhibit cytotoxic effects of the engineered immune cell on the healthy cell,
- simultaneously, a second set of the activating and blocking receptors collect into a second cell-surface region of the engineered immune cell proximal to the tumor cell in which the activating receptors promote a cytotoxic response by the engineered immune cell that kills the tumor cell.
Dependencies are inferred from the claim text.